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Organisms of the Burkholderia cepacia complex are especially important pathogens in cystic fibrosis (CF), with a propensity for
patient-to-patient spread and long-term respiratory colonization. B. cenocepacia and Burkholderia multivorans account for the
majority of infections in CF, andmajor epidemic clones have been recognized throughout the world. The aim of the present
study was to develop and evaluate a multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) scheme for B. cenoce-
pacia. Potential VNTR loci were identified upon analysis of the annotated genome sequences of B. cenocepacia strains AU1054,
J2315, andMCO-3, and 10 of them were selected on the basis of polymorphisms and size. A collection of 100 B. cenocepacia
strains, including epidemiologically related and unrelated strains, as well as representatives of the major epidemic lineages, was
used to evaluate typeability, epidemiological concordance, and the discriminatory power of MLVA-10 compared with those of
pulsed-field gel electrophoresis (PFGE) andmultilocus sequence typing (MLST). Longitudinal stability was assessed by testing 39
successive isolates from 14 patients. Typeability ranged from 0.91 to 1, except for that of one marker, which was not amplified in
53% of the B. cenocepacia IIIA strains. The MLVA types were shown to be stable in chronically colonized patients and within
outbreak-related strains, with excellent epidemiological concordance. Epidemic and/or globally distributed lineages (epidemic
Edinburgh-Toronto electrophoretic type 12 [ET-12], sequence type 32 [ST-32], ST-122, ST-234, and ST-241) were successfully
identified. Conversely, the discriminatory power of MLVAwas lower than that of PFGE orMLST, although PFGE variations
within the epidemic lineages sometimes masked their genetic relatedness. In conclusion, MLVA represents a promising cost-
effective first-line tool in B. cenocepacia surveillance.
The Burkholderia cepacia complex (BCC), which includes 18closely related species, is mainly involved in pulmonary infec-
tions in patients with cystic fibrosis (CF), although it is also occa-
sionally recovered in nosocomial infections and/or from immu-
nocompromised hosts. BCC infection in CF patients is associated
with accelerated decline of lung function, cepacia syndrome, and
poor posttransplantation outcome. The most frequently recov-
ered species of the BCC are B. cenocepacia and Burkholderia mul-
tivorans, which have been found to be responsible for large out-
breaks among CF patients, prompting the implementation of
infection control measures and epidemiological surveillance. B.
cenocepacia consists of four recA subgroups: IIIA, which includes
the Edinburgh-Toronto electrophoretic type 12 (ET-12) epidemic
lineage (in Canada and the United Kingdom) (1); IIIB, which
includes the PHDC epidemic lineage (in the United States) (2)
and theMidwest clone (3); IIIC, which is exclusively environmen-
tal; and IIID, which was reported to be responsible for 50% of the
BCC infections in an Italian CF center (4).
Putative transmissibility markers have been identified within
B. cenocepacia epidemic strains. The cblA pilin gene is character-
istic of ET-12 strains (5). The B. cepacia epidemic strain marker
(BCESM), which is part of a pathogenicity island, was identified in
ET-12 strains and in other epidemic lineages but also in unique
clinical or environmental strains (6, 7), whereas the PHDC lineage
is BCESM negative. Finally, the IS1363 insertion sequence was
demonstrated to be characteristic of the PHDC and ET-12 line-
ages (8). Thus, some epidemic lineages are associated with genetic
markers, but none of these proved to be universal, and epidemio-
logical surveillance still requires genotyping studies.
Several typing methods have been developed to trace BCC or-
ganisms. Among them, pulsed-field gel electrophoresis (PFGE)
and multilocus sequence typing (MLST) are currently considered
the gold standard methods for epidemiological typing and popu-
lation genetics studies. PFGE has been extensively used to charac-
terize outbreaks but is a rather laborious technique that requires 9
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days to generate typing results. Another limitation of PFGE typing
is the difficulty in comparing the fingerprints between laborato-
ries, especially when different protocols and similarity thresholds
for clonal delineation are used. MLST offers the advantage of be-
ing a truly portable method that allows the generation of coded
types and easily accessible databases.However,MLST costs are too
high for routine use in the clinical microbiology laboratory or for
the characterization of large numbers of BCC strains in national
surveillance programs. Additional typing methods combining
good interlaboratory reproducibility with high discrimination,
meaningful epidemiological inference, and low cost are still
needed.
Tandem repeats (TR) consist of consecutive occurrences of a
more or less identical DNA repeat unit. They are found in the
chromosomes of most organisms, from prokaryotes to eu-
karyotes, and some TR show intraspecies polymorphisms. Al-
though the biological function and evolution mechanism(s) of
these loci with variable-number tandem repeats (VNTRs) are
not yet fully understood, they have found several practical ap-
plications in epidemiological typing. Multilocus VNTR analy-
sis (MLVA) is one of the most promising techniques for tracing
the epidemiology of bacteria and has become the reference
typing method in several bacterial species (9–13). In a typical
MLVA assay, a predefined number of VNTRs is analyzed by
PCR amplification, followed by electrophoresis to estimate the
size of the PCR products. A code reflecting the number of re-
peats at each locus can be determined for individual strains.
Therefore, MLVA is a cost-effective typing method that pro-
vides portable results, with the MLVA codes consisting of an
unequivocal string of numbers that can easily be exchanged
between laboratories and made accessible via internet data-
bases (12). MLVA codes can also be deduced from whole-
genome sequence data (14). An MLVA scheme has been devel-
oped to type Burkholderia pseudomallei (15, 16).
The aim of this study was to establish an MLVA scheme for B.
cenocepacia. For this purpose, we searched for the presence of
shared VNTRmarkers in the complete genome sequences of four
B. cenocepacia strains and set up a standardMLVA protocol based
on simple PCR and agarose gel electrophoresis. The overall per-
formances of the MLVA method were assessed in a study of a
selected collection of B. cenocepacia strains and compared with
those of reference typing methods, including PFGE and MLST.
MATERIALS AND METHODS
Bacterial strains. A total of 109 strains were used in the present study,
which included 25 reference strains and 84 strains from the French Ob-
servatoire Burkholderia cepacia (OBC) collection. The 25 reference strain
panel included seven B. cenocepacia IIIA strains (J2315, LMG18827,
LMG18826, LMG18863, LMG6981, LMG18828, and LMG6986), nine B.
cenocepacia IIIB strains (AU1054, LMG16659, LMG18829, LMG18830,
LMG13011, LMG14271, LMG14274, LMG14276, and LMG16654), eight
B. cenocepacia IIIC strains (LS2.4, Aus26, Aus12, Aus31, Aus32, Aus34,
Aus13, and WS11.7, referred to in the LMG collection as LMG19233,
LMG19247, LMG19243, LMG19244, LMG19248, LMG19242, LMG19240,
and LMG19232, respectively), and one B. cenocepacia IIID strain
(LMG21461). Strain AU1054 (PHDC lineage) was kindly provided by
John LiPuma, University of Michigan, Ann Arbor, MI, USA, and strain
J2315 (ET-12 lineage) by Catherine Doherty, University of Edinburgh,
Edinburgh, Great Britain; other clinical strains were obtained from the
LMG collection, Ghent, Belgium. The environmental B. cenocepacia IIIC
strains were kindly provided by Jacques Balandreau, UMR 5557 CNRS,
Université Claude Bernard, Lyon, France. Nine reference strains were part
of the diagnostically and experimentally useful panel of strains of the BCC
(17). The panel of 84 nonredundant clinical strains from the OBC collec-
tion included epidemiologically related and unrelated strains (Table 1; see
also Table S2 in the supplemental material) and comprised 72 CF strains
from20CF centers, as well as 12 non-CF strains. These 84 strains had been
tested with the species-specific recA-based PCRs described by Mahenthi-
ralingam et al. (18), and 46 were assigned to B. cenocepacia IIIA and 37 to
B. cenocepacia IIIB. One strain was species-specific PCR negative and was
subsequently identified as B. cenocepacia IIID bymeans of recA sequenc-
ing.
Also, 39 clinical isolates recovered from 14 patients (two to four suc-
cessive isolates per patient sampled over a mean period of 4.7 years) were
included to assess the in vivo stability of the MLVA results (longitudinal
stability panel; see Table S1 in the supplemental material).
Selection of VNTR markers. The annotated genome sequences of
strain AU1054 (GenBank accession no. NC_008060, NC_008061, and
NC_008062), J2315 (NC_011000, NC_011001, and NC_011002), and
strain MCO-3 (NC_010508, NC_010512, and NC_010515) were in-
spected for the presence of potential VNTR loci by using the strain com-
parison tool available at the Microorganisms Tandem Repeats Database
(http://tandemrepeat.u-psud.fr/). Ten VNTRs were selected on the basis
of polymorphisms and repeat size (Table 2). The full locus names
include the following allele calling convention: repeat unit size, ex-
pected PCR product size with the indicated primers in the first pub-
lished complete genome sequence (J2315), and corresponding repeat
unit number assigned by convention (for example, BcenM01_49bp_
399bp_4U). Abbreviated names (BcenM01) are used here for simplifi-
cation.
Nomenclature and description of MLVA profiles. The expected am-
plicon size, repeat length, and number of repetitions were determined in
reference genomes of the AU1054, MC0-3, and J2315 strains available at
the National Center for Biotechnology Information (see http://www.ncbi
.nlm.nih.gov/sites/genome), using the PCR primer BLAST tool from the
Microorganisms Tandem Repeats Database and an in silicoMLVA typing
tool (see http://mlva.u-psud.fr). The number of repeats was calculated
according to an excess approximation in order to consider also the non-
integer number of repeats in the allele counts, as explained in Vergnaud
and Pourcel (10, 13). The length of the individual repeats within some of
the tandem repeats showed variations (Table 2), but repeat copy numbers
were unambiguously derived from size estimates, mostly due to large
repeat units and moderate repeat copy numbers. The allelic profile was
defined as the number of repeats at each VNTR locus included in the
MLVA scheme.When no amplificationwas repeatedly observed at a given
locus, the value “0” was assigned to the corresponding allele.
TemplateDNA forPCRs.Bacterial thermolysateswere prepared from
overnight cultures using a rapid procedure; four colonies were suspended
in 200l of sterile water, incubated 10 min at 95°C, frozen at20°C, and
thawed. The supernatant was recovered after centrifugation and stored at
20°C.
PCR amplification of VNTR loci. The primers used are described in
Table 2. PCR was performed in a reaction volume of 25l containing 1
PCR buffer, 1.5 mMMgCl2, 1 M betaine (Sigma-Aldrich, Saint-Quentin-
Fallavier, France), 1 U of Taq DNA polymerase (Eurobio, Les Ulis,
France), 200 M each deoxynucleoside triphosphate (Eurobio), 0.2 M
each primer (Eurofins MWG Operon, Les Ulis, France), and 2.5 l of
DNA template. Amplification was carried out using a VWRDoppio ther-
mal cycler, under the following conditions: initial denaturation at 96°C
for 4 min, 30 cycles of denaturation at 96°C for 30 s, annealing at 60°C for
1 min, and elongation at 72°C for 1 min, and a final elongation step at
72°C for 5 min. One microliter of PCR product was separated in 2% (for
BcenM01, BcenM02, BcenM03, BcenM04, BcenM07, and BcenM10),
1.5% (for BcenM05 and BcenM09), or 1% (BcenM06 and BcenM08)
(wt/vol) agarose gels (Resophor; Eurobio) in Tris-borate-EDTA (TBE)
buffer (Euromedex, Souffelweyersheim, France). The PCR products from
MLVA of Burkholderia cenocepacia Complex
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strains J2315 and AU1054 (of a known expected size), and two DNA size
markers, i.e., 50-bp DNA ladder and pUC mix marker 8 (Fermentas,
Villebon-sur-Yvette, France), were included in each run to allow size as-
signment.
Performance criteria for evaluation of MLVA typing. MLVA was
evaluated according to theGuidelines for the validation and application of
typing methods for use in bacterial epidemiology (19).
The interlaboratory reproducibility of MLVA was tested on 11 of the
25 reference strains, composed of seven clinical strains (LMG16656,
LMG18827, LMG18826, LMG24506, LMG6981, LMG18828, and
LMG16659) and four environmental strains (LMG19232, LMG19233,
LMG19243, and LMG19248). MLVA was performed at the University
Paris Sud,Orsay laboratory, and in theObservatoireB. cepacia laboratory,
Toulouse, France, and the results were compared.
Typeability (T)was assessed for each of the 10VNTR loci tested (Table
2). Strains for which two ormore VNTRs were not amplified were further
submitted to recA sequencing in order to ascertain that their initial iden-
tification as B. cenocepacia by IIIA- or IIIB-specific PCR positivity was
correct.
In vivo longitudinal stability (LS) was assessed by testing the longitu-
dinal stability panel (see Table S1 in the supplemental material). In vivo
transversal stability (TS) was assessed by comparing theMLVA profiles of
25 outbreak-related strains belonging to the three genotypes involved in
major outbreaks in France and referred to as genotypes 2, 3, and 11 in a
previous study (20) (Table 1).
Epidemiological concordance (E) was assessed by testing 39 strains,
which included the abovementioned 25 outbreak-related clinical strains,
six epidemiologically related strains involved in cross-transmission, four
strains belonging to the ET-12 lineage, and four environmental reference
strains of B. cenocepacia IIIC belonging to the same sequence type (ST-
118).
Discriminatory power was evaluated using a panel of 60 epidemiolog-
ically unrelated clinical strains belonging to the IIIA (36 strains) and IIIB
(24 strains) subgroups, which included 10 reference strains and one strain
of each epidemic clone (see Table S2 in the supplemental material). The
Hunter-Gaston discriminatory index (HGDI) and 95% confidence inter-
val were calculated using the BioNumerics software version 7.1 (Applied
Maths, Sint-Martens-Latem, Belgium).
The MLVA typing results were compared to the results obtained by
PCR ribotyping (21) routinely used for epidemiological screening in the
Observatoire B. cepacia laboratory and PFGE, performed as previously
described (20).
Finally, the unweighted-pair group method using average linkages
(UPGMA) was used for clustering analysis and dendrogram generation
(BioNumerics).
recA sequencing andMLST. recA sequencing was performed on non-
typeable strains according to Mahenthiralingam et al. (18), and the se-
quence data were analyzed using the Basic Local Alignment Search Tool
(BLAST) (www.ncbi.nlm.nih.gov/BLAST/).
A selection of strains was subjected to MLST using the scheme pro-
posed by Baldwin et al. (22). Amplification was performed in a reaction
volume of 50 l containing 1 PCR buffer, 1.5 mMMgCl2, 1 M betaine,
1.5 U of Taq DNA polymerase, 200 M each deoxynucleoside triphos-
phate, 0.4 M each primer, and 4 l of DNA template. Amplified DNA
was purified using the QIAquick PCR purification kit (Qiagen, Courta-
boeuf, France). DNA concentration and purity were assessed using spec-
trophotometric analysis (BioPhotometer; Eppendorf, Le Pecq, France)
and DNA concentrations adjusted to 10 ng/l. The sequencing reactions
were performed by the genomic facility GeT-Purpan of the Genomic and
Transcriptomic Platform, Génopole Toulouse-Midi-Pyrénées, using the
ABI Prism BigDye Terminator version 3.1 cycle sequencing kit (Applied
Biosystems, Foster City, CA) and the 3130XL genetic analyzer (Applied
Biosystems). The B. cepacia complex MLST website (http://pubmlst.org
/bcc/) developed by Keith Jolley and located at the University of Oxford,
Oxford, United Kingdom (23) was used for the MLST analysis.
IS1363-specific PCR.The primers P1 (5=-GCTTAATAGGATGGTCA
G-3=) and P2 (5=-TCCATGACCACCGTACAACTC-3=) were those de-
scribed by Liu et al. (8). PCR was performed in a reaction volume of 25l
containing 1 PCR buffer, 1.5 mMMgCl2, 1 U of Taq DNA polymerase,
200Meachdeoxynucleoside triphosphate, 0.6Meachprimer, and 4l
of DNA template. DNA from strain AU1054 was used as a positive con-
trol. Amplification was carried out under the following conditions: initial
denaturation for 5 min at 95°C, 30 cycles of 45 s at 95°C, 45 s at 55°C, and
45 s at 72°C, with a final extension step of 10 min at 72°C. The PCR
products were separated in 1.5% (wt/vol) agarose gels (Eurobio) in TBE
buffer.
RESULTS
VNTR identification and interlaboratory reproducibility. Four-
teen VNTRs were identified by a genome comparison of three
available sequenced strains. Ten were subsequently retained on
the basis of a minimum repeat size of 15 bp and more than one
allele within the 11 reference strains constituting the test panel for
reproducibility (Table 2). The MLVA results were identical in
both laboratories for the 11 strains.
Typeability. Amplification failures were observed at two,
three, or four VNTRs in 18 of the 109 strains tested: 8/18 were
environmental B. cenocepacia IIIC strains, which were all negative
for at least BcenM07 and BcenM08; five were IIIA recA-based
specific PCR positive, and subsequent recA sequencing identified
four of them as B. contaminans (with at least BcenM07, BcenM08,
and BcenM10 being negative) and the last one as Burkholderia
cenocepacia IIIA; last, five were IIIB recA-based specific PCR pos-
itive, and subsequent recA sequencing identified them as belong-
ing to the BCC6 group described byDalmastri et al. (24). The nine
BCC6 group and B. contaminans strains were excluded from fur-
ther analysis, which was consequently based on 100 B. cenocepacia
strains (Table 2). Individual marker typeability was found to be
0.98 for six markers (BcenM01 to BcenM06) and 0.91 for three
markers (BcenM07, BcenM08, and BcenM10). Last, BcenM09
amplification failure was observed in 26 of the 49 B. cenocepacia
IIIA strains (53%), in contrast with the full BcenM09 typeability of
other subgroups. The global T values for the MLVA-10 scheme
were 0.43 forB. cenocepacia IIIA strains and 0.80 forB. cenocepacia
IIIB strains. The low global typeability of B. cenocepacia IIIA
strains is partly due to the overrepresentation (11/49) of ST-32
strains, for which BcenM09 amplification was never obtained. In
addition, BcenM09 was not amplified in three strains sharing the
PCR ribotype CE and the PFGE type DE (ST-201). Thus, consid-
ering the absence of BcenM09 amplification as a signature for
ST-32 and ST-201 strains, it is possible to evaluate BcenM09 type-
ability as 0.76 and the global typeability of B. cenocepacia IIIA
strains as 0.69.
Allelic variation. The number of alleles of the different mark-
ers ranged from three to seven within the 100 tested strains (Table
2). Of note is that all the strains of B. cenocepacia IIIA tested in this
study (n 49) were monomorphic with regard to the number of
repeat units of BcenM04 (three repeat units, with the exception
of two amplification failures), BcenM05 (two repeat units),
BcenM06 (one repeat unit), and BcenM07 (two repeat units), and
they were almost monomorphic at BcenM10 (mostly three repeat
units except for one strain). Figure 1 shows an example of an
electrophoretic analysis of VNTR polymorphisms.
Longitudinal stability. The longitudinal stability panel (see
Table S1 in the supplemental material) included 39 isolates from
14 patients. Nine patients were colonized with B. cenocepacia IIIA
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and five with B. cenocepacia IIIB. The mean time between the first
and the last isolate was 4.7 years (range, 1.1 to 10.2). In 12 of the 14
patients (86%), the MLVA profiles were identical over time. In
two patients, a difference at BcenM08 was observed in one of the
isolates tested, i.e., one amplification failure and a deletion of one
repeat. Thus, an LS value of 1.00 was achieved for all markers
except BcenM08 (LS, 0.90).
Transversal stability and epidemiological concordance.
Twenty-five French outbreak-related strains, involving three epi-
demic lineages, were tested. All strains within each epidemic line-
age harbored the same MLVA profile, with the exception of two
amplification failures (at BcenM02 and BcenM10). Thus, a TS
value of 1.00 was achieved for all markers. except BcenM02 and
BcenM10 (TS, 0.96).
Two pairs of French epidemiologically related strains showed
the same MLVA type, and within a third pair, the only difference
was that BcenM04 failed to be amplified in one isolate. Similarly,
four strains belonging to theB. cenocepacia IIIA ET-12 lineage and
four ST-118 environmental B. cenocepacia IIIC strains were iden-
tical. In conclusion, epidemiological concordance assessed using
39 epidemiologically related strains showed an E value of 0.92
(Table 1).
Discriminatory power. The discriminatory power of the
MLVA scheme was assessed using a panel of 60 epidemiologically
unrelated strains (see Table S2 in the supplemental material). The
HGDI values and 95% confidence intervals are reported in Table
2. An HGDI value of 0.98 was observed when the 10 VNTRs
were combined. Five of the 10 markers (BcenM01, BcenM03,
BcenM04, BcenM08, and BcenM09) were highly discriminating
(HGDI, 0.6), whereas the remaining markers provided HGDI
values of 0.42 to 0.59. A marked difference was observed between
the IIIA and IIIB strains.Within the IIIA strains, only three mark-
ers (BcenM03, BcenM08, and BcenM09) provided HGDI values
of 0.6, whereas five markers provided HGDI values of 0.3.
However, the combined indexwas similar for both groups, reflect-
ing the marker complementarities. The numbers of IIIC and IIID
strains included in the present study were low (eight and two
strains, respectively), and allelic variation was observed with
only two markers (BcenM02 and BcenM05 and BcenM05 and
BcenM08, respectively).
Comparison of MLVA and PFGE within B. cenocepacia IIIA
and IIIB strains. PFGE results were available for 82 strains, which
included 44 B. cenocepacia IIIA and 38 B. cenocepacia IIIB strains,
and these were comparedwith the results ofMLVA typing. Strains
exhibiting contradictory PFGE and MLVA classifications were
submitted to MLST. The 82 strains were distributed into 41
MLVA types and 47 PFGE types.
Fifty-three strains were classified into 12 shared MLVA types
that included 2 to 10 strains, as well as 24 PFGE types. Of the 12
shared MLVA types, two (A5 and B2) included epidemiologically
related strains only, three (A1, A3, and B1) included epidemiolog-
ically related andunrelated strains, six (A4, A12, A20, A18, B5, and
B8) included epidemiologically unrelated strains only, and the last
one (B4), had strains LMG14274, LMG14276, and LMG13011,
which were recovered from CF patients in Belgium. The PFGE
results were in agreementwith theMLVA classificationswithin six
of these 12 sharedMLVA types, i.e., A12, A20, A5, B2, B4, and B5,
which encompassed 22 strains. Conversely, several PFGE types
were differentiated within the six remaining shared MLVA
types consisting of 31 strains. The 25 strains belonging to MLVA
types A1, B1, and A3 were distributed into three, five, and four
PFGE types, respectively, whereas MLST analysis grouped the
MLVA type A1 strains into ST-32, MLVA type B1 strains into
ST-122, and MLVA type A3 strains into three very close STs (ST-
276, ST-234, and ST-869, with two nucleotides difference). Two
pairs of B. cenocepacia IIIA epidemiologically unrelated strains
shared a PCR ribotype (FK andCU, respectively) andMLVA types
(A4 and A18, respectively) but were classified into different PFGE
types anddifferent STs,mainly due to differences in the gyrB allele.
Finally, two strains of B. cenocepacia IIIB classified into the B8
FIG 1 Electrophoretic analysis of the number of tandem repeats at each VNTR. Lane 1, 50-bp DNA ladder; lane 2, strain J2315 (LMG16656); lanes 3 to 6, four
of the strains tested in the present study; lane 7, strain AU1054 (LMG24506); lane 8, pUC mix marker 8. The numbers of tandem repeats (U) are indicated for
J2315 and AU1054 strains, used as controls. The arrows indicate fragment sizes of the DNA ladders.
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MLVA type were different by all the other techniques. Within the
nine shared MLVA types that included epidemiologically unre-
lated strains, four match globally distributed STs (MLVA type
A1/ST-32, MLVA type A3/ST-234, MLVA type A20/ST-241, and
MLVA type B1/ST-122), and two match STs reported in another
country (MLVA type A12/ST-201 andMLVA type A18/ST-665 in
Italy and New Zealand, respectively) (http://pubmlst.org/bcc).
Twenty-nine strains were classified into 29 unique MLVA
types and 24 PFGE types. Twenty of these 29 strains were classified
into unique MLVA types and unique PFGE types. Three strains
with unique MLVA types (21_17/MLVA type A24, 17_29/MLVA
type B21, and 22_78/MLVA type A26) classified into shared PFGE
types (BD, C, and HB, respectively) were part of the epidemiolog-
ically related panel and differed from the other strains harboring
the same PFGE type by a “0” allele at one locus. Two pairs of
epidemiologically unrelated strains (12_03 and 22_59, and 05_12
and 9_54) were classified into shared PFGE types (GO and C,
respectively) and shared STs (844 and 279, respectively). One pair
of epidemiologically unrelated strains (20_77 and 20_78) was
classified into the same PFGE type (FY) and two different STs
(ST-760 and ST-845, 8 nucleotides difference).
In conclusion, MLVA classification was in agreement with
PFGE and/or MLST in 69 of 82 strains (84%).
Population analysis. UPGMA analysis showed that MLVA
classification was in agreement with recA classification, with the
exception of two IIIB strains. A cutoff of 85%was used to delineate
clusters, corresponding to a maximum of one difference among
the 10 loci (Fig. 2).
Four clusters designated IIIB-C1 to -C4were delineated within
B. cenocepacia IIIB strains, which included 26 of the 41 tested
strains. MLVA clusterization within the B. cenocepacia IIIB iso-
lates fit with epidemiological and/or genetic relatedness: cluster
IIIB-C1 consisted of Belgian CF strains, cluster IIIB-C2 of ST-279
strains (French epidemic type 11, reported only in France to-
date), cluster IIIB-C3 of ST-122 strains, including the PHDC
North American epidemic strain and outbreak-related CF strains
(French epidemic type 2), and cluster IIIB-C4 of epidemiologi-
cally unrelated strains (two CF and one non-CF), which exhibited
the samePFGE type. Following the identification of French strains
harboring the same MLVA type as strain AU1054/LMG24506
(PHDC B. cenocepacia IIIB lineage), characterized by the presence
of IS1363, an IS1363-specific PCRwas performed inB. cenocepacia
IIIB-PCR-positive strains. Strain OBC08_30, which was classified
in cluster IIIB-C3 but belongs to ST-37 (10 nucleotide and 3 allele
differenceswith ST-122)was IS1363positive.Of note is that fiveB.
cenocepacia IIIB strains were found to be IS1363 positive outside
the IIIB-C3 cluster.
Six clusters designated C1 to C6 were delineated within the B.
cenocepacia IIIA strains, which included 35 of the 49 strains tested.
MLVA clusterization within the B. cenocepacia IIIA isolates fit
with epidemiological and/or genetic relatedness for five of the six
clusters: cluster IIIA-C1 was composed of ET-12 strains (and of a
FrenchCF strain), cluster IIIA-C2 and IIIA-C5of groups of strains
belonging to very close STs (one to two nucleotides difference),
IIIA-C4 of strains classified into the same PCR ribotype and PFGE
type, and IIIA-C6 of ST-32 strains (French epidemic type 3). On
the contrary, cluster IIIA-C3 was heterogeneous (six strains, four
PCR ribotypes, five PFGE types, and five markedly different STs).
Lowering the cutoff to 58% classified nearly all the B. cenoce-
pacia IIIA strains into the same group but delineated five groups
within the B. cenocepacia IIIB strains.
DISCUSSION
BCCorganisms are recognized as important pathogens inCF.Due
to their ability to spread from patient to patient, they have been
involved in large outbreaks.While PCR-basedmethods and PFGE
have successfully been applied to local epidemiology, large-scale
analyses requiremore portablemethods, such asMLST orMLVA.
An MLST scheme based on seven housekeeping genes has been
developed and applied to global epidemiological analyses (22, 25).
Also, the recA gene included in the MLST scheme allows the dis-
crimination of species within the BCC. MLVA is also a transfer-
able typing method, which is increasingly used to trace bacterial
epidemiology. In the present study, we established an MLVA-10
scheme for the typing of B. cenocepacia strains, which together
with B. multivorans predominates in CF and is associated with
highly transmissible lineages, such as the so-called ET-12, ST-32
(B. cenocepacia IIIA), Midwest, and PHDC (B. cenocepacia IIIB)
lineages. Within the selected markers, the size of the repeat unit
varied from 15 to 75 bp, which allows for allele assignment by
means of simple agarose gel electrophoresis. The performance of
MLVA-10 was evaluated on a large representative collection of
epidemiologically related and unrelated national and interna-
tional strains.
The selected VNTRs appear to be specific for B. cenocepacia, as
B. contaminans and the BCC6 group strains failed to be amplified
at two to four loci when using the proposed PCR primer pairs. An
examination of the sequenced genomes confirmed that the VN-
TRs cannot be amplified in silico in other members of the BCC.
Moreover, these loci are not equally spread within the subgroups
of the B. cenocepacia species. BcenM09 failed to amplify in more
than half of the B. cenocepacia IIIA strains tested, whereas it was
amplified in all the B. cenocepacia IIIB, IIIC, and IIID strains
tested. BcenM07 and BcenM08 failed to amplify in the eight B.
cenocepacia IIIC strains tested, whereas they were amplified in all
but one of the 92 strains belonging to other subgroups. Neverthe-
less, the absence of BcenM09 may be considered a marker for
someB. cenocepacia lineages (ST-32 and ST-201), and the fact that
B. cenocepacia IIIC strains are not fully typeable with the proposed
scheme is not expected to impact the performance of MLVA for
the typing of clinical strains, since subgroup IIIC has until now
been recovered from the natural environment only.
Stability is of the utmost importance in BCC epidemiology,
since most colonizations are chronic and since patient-to-patient
spread may be observed over years. We checked the stabilities of
the selected VNTR loci in 14 patients by testing up to four succes-
sive isolates per patient. TheMLVA patterns were stable over time
in 13 patients (92.8%), and the variation observed in one patient
concerned a single VNTR (BcenM08, with a loss of one repeat
unit). Comparatively, the longitudinal stability of the MLST re-
sults for 41 BCC isolates from 20 patients showed no change in 15
patients (75%), strain replacement in one patient, and changes
due to recombination events in four patients (20%) colonized
with B. multivorans (one patient), B. vietnamiensis (two patients),
or B. cenocepacia IIIA (one patient) (26). If this trend was con-
firmed by larger investigations, then one might speculate that al-
lelic differences at VNTR loci in the BCC may prevent recombi-
nation, and it would explain the stability of MLVA compared to
that of theMLST profiles. In order to validate the use ofMLVA for
MLVA of Burkholderia cenocepacia Complex
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identifying outbreaks, we tested multiple strains of the three epi-
demic lineages of B. cenocepacia, i.e., ST-32, ST-279, and ST-122,
responsible for outbreaks in one (ST-122) or several (ST-32 and
ST-279) French CF centers in the late 1980s to the early 1990s.We
included strains from each of the CF centers, collected over peri-
ods of 11 to 22 years, and demonstrated the long-term transversal
stability of the MLVA profiles, with the exception of two amplifi-
cation failures. Of note is that a loss of one BcenM08 repeat
unit was observed in one outbreak-unrelated ST-279 strain
(OBC09_54). Thus, the marker BcenM08 might be slightly less
stable than the othermarkers, since it alsowas the singlemarker to
vary in one patient who was included in the longitudinal study.
Whereas the PFGE types were identical within all the ST-279
strains tested, two, two, and five PFGE types were observed within
the globally distributed lineage ST-32, ST 234, and ST-122
(PHDC) strains, respectively. PFGE pattern variability was previ-
ously reported by Drevinek and Mahenthiralingam (27) within
the ST-32 Czech strains, and it was attributed to IS-mediated
genomic rearrangements. Similar variability was reported by
Campana et al. (28) within the Italian PHDC strains. It can be
hypothesized that due to the presence of several copies of IS1363
in PHDC strains (8), ISmovementsmight also interferewithmac-
rorestriction-based types within this lineage. Interestingly, we
demonstrated the presence of IS1363 in 16 of the 41 B. cenocepacia
IIIB strains tested, six of which were different from the PHDC
lineage. Lastly, the four tested ET-12 strains exhibited the same
MLVA type, whereas they belong to four different STs identified
within Canadian ET-12 strains. In contrast, all reported ET-12
strains in the United Kingdom were found to belong to ST-28
(29). Thus, the evolution rates andmechanismswithin eachmajor
clonal complex seem different, with variable consequences ac-
cording to the typing method, leading to difficulties in establish-
ing a unique gold standard for genotyping. This is in agreement
with a previous study using multilocus restriction typing (MLRT)
(30), showing differences in population structures among the ET-
12, PHDC, and Midwest lineages, which were attributed to vari-
ous degrees of genetic recombination. Finally, the MLVA-10 sig-
natures of other epidemic strains, i.e., LMG18829 (ST-40,
Midwest clone) and LMG16659 (ST-35, Manchester epidemic
clone), were shown to be specific within the collection tested. On
the contrary, LMG18830 (ST-36, Sydney epidemic clone) and a
non-CF strain from La Réunion Island were classified in the same
MLVA type but into different PCR ribotypes, PFGE types, and
MLST profiles. This might be attributed to homoplasy, i.e., evo-
FIG 2 MLVA-basedUPGMA clustering analysis of the B. cenocepacia strains included in the present study (cutoff, 80%). Strains classified in the same cluster are
indicated using colored squares. Under the source column, there are clinical (C) and environmental (E) strains. ID, identification; CF, cystic fibrosis.
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lutionary convergence or reversion to an ancestral profile. Thus,
in spite of one discordance, MLVA-10 seems a valuable tool for
recognizing outbreaks and identifying widely distributed and/or
epidemic lineages.
Within the 10markers used, the number of alleles ranged from
three to seven, and the diversity index (HGDI) for individual loci
ranged from 0.42 to 0.73. The HGDI value for the MLVA-10
schemewas of 0.98, thus fulfilling the European Society of Clinical
Microbiology and Infectious Diseases Study Group on Epidemi-
ological Markers (ESGEM) criteria (0.95) (19). Compared to
PFGE within epidemiologically unrelated strains, the discrimina-
tory power of MLVA-10 seems lower than that of PFGE, which
was confirmed by MLST, although the reverse situation has also
been observed. Concordance of MLVA with PFGE and/or MLST
results was shown to be 84% within the collection tested.
MLVA-based population structure was in agreement with recA
classification, with the exception of two IIIB strains, which might
represent a specific subgroup. Heterogeneity was higher within
the B. cenocepacia IIIB strains than within the B. cenocepacia IIIA
strains, since three of the 10 loci were found to be homogeneous
within the B. cenocepacia IIIA strains, which were nearly all classi-
fied in a unique group using a cluster delineation cutoff of 58%.
This may be due to a lower discriminatory power of the scheme
used within IIIA strains, but it is in agreement with an MLST-
based population structure. Using thematches of five out of seven
loci, 198 of the 212 B. cenocepacia IIIA strains included in the
MLST database are brought together in a large clonal complex,
with ST-234 as a potential ancestral type. In contrast, the 155 B.
cenocepacia IIIB strains are distributed into 10 clonal complexes
and 81 singletons (http://pubmlst.org/bcc/).
In conclusion, due to the high genomic plasticity of B. cepacia
complex organisms, recombination events or IS movements may
interfere with genotyping methods and mask epidemiological re-
latedness. The MLVA-10 scheme developed in the present study
was shown to be an appropriate tool to detect epidemic strains of
B. cenocepacia, due to the high stability of MLVA profiles, the
satisfactory discriminatory power, and the portability of the
method, allowing the establishment of a Web-based database
(http://mlva.u-psud.fr) (14). We suggest the use of MLVA as a
first-line typing method for B. cenocepacia and further analyses of
the representative MLVA profiles by means of MLST. This ap-
proach would be cost-effective, since in our laboratory, the re-
FIG 2 continued
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agents and sequencing costs for the characterization of one strain
by means of recA sequence for species identification plus
MLVA-10 were 36 euros compared to 112 euros for MLST analy-
sis, with comparable hands-on time. Besides, the MLVA-10
scheme could easily be automated using fluorescent primers and a
single multiplex PCR (31). Capillary electrophoresis would allow
automatic size measurement of the PCR products and thus in-
crease the accuracy of repeat number determination, as described
for other bacterial species (31–33). Furthermore, some potentially
informative VNTR markers that were ruled out from the pres-
ent scheme due to short repeats (15 bp) could be included to
constitute a second panel with high discriminatory power, as
has been proposed for other bacteria (34). Nevertheless, in
contrast with MLST, which has the advantage of being usable
for the whole BCC, species-specific MLVA schemes have to be
developed, and the establishment of a B. multivorans MLVA
scheme is in progress.
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